Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Dinutuximab beta
Synonyms
Therapy Description

Dinutuximab beta (ch14.18/CHO) is biosimilar of the anti-GD2 antibody Unituxin (dinutuximab) produced in CHO cells, with a different glycosylation pattern than dinutuximab, which potentially induces antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells, and reduces liver metastasis (PMID: 30613134, PMID: 15950727).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Dinutuximab beta ch14.18/CHO|APN311|APN-311|APN 311|Qarziba Dinutuximab beta (ch14.18/CHO) is biosimilar of the anti-GD2 antibody Unituxin (dinutuximab) produced in CHO cells, with a different glycosylation pattern than dinutuximab, which potentially induces antibody-dependent and complement-dependent cytotoxicity against GD2-expressing tumor cells, and reduces liver metastasis (PMID: 30613134, PMID: 15950727).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01704716 Phase III Busulfan + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Filgrastim Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Dinutuximab beta Aldesleukin + Dinutuximab beta Carboplatin + Etoposide + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) Recruiting ITA | GBR | FRA | ESP | BEL | AUT | AUS 13
NCT04221035 Phase III Busulfan + Melphalan + Thiotepa Dinutuximab beta Cisplatin + Etoposide + Vindesine Dacarbazine + Doxorubicin + Ifosfamide + Vincristine Sulfate Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate Busulfan + Melphalan High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) Recruiting ITA | GBR | FRA | ESP | BEL | AUS 10


Additional content available in CKB BOOST